1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Doximity disclosed that Chief Financial Officer Anna Bryson, who had been on medical leave, resigned on April 13, 2026, and that Chief Accounting Officer Siddharth Sitaram has served as interim principal financial and accounting officer since February 3, 2026. The company also reaffirmed its guidance for the fourth quarter and full fiscal year ending March 31, 2026, given on February 5, 2026, which matters to shareholders because it signals no change to prior expectations despite the leadership transition.
CFO Anna Bryson resigned; the company accepted her resignation on April 13, 2026
Siddharth Sitaram, Chief Accounting Officer, serves as interim principal financial and accounting officer, effective February 3, 2026
Company reaffirmed fourth quarter and full fiscal year 2026 guidance first given February 5, 2026
Company expects to update on the CFO search during its next earnings call
Carpenter Technology's board increased its size from 11 to 12 directors and appointed Brian J. Malloy, the company's current President and Chief Operating Officer, as a director effective July 1, 2026. On the same date, Malloy becomes President and Chief Executive Officer, and current CEO Tony R. Thene becomes Executive Chairman of the Board, so the company's top executive role changes hands.
On April 13, 2026, the board expanded from 11 to 12 directors and appointed Malloy as a Class III director, with a term ending at the 2028 annual meeting; he has no committee appointments yet.
Malloy will become President and CEO on July 1, 2026, with a $1,000,000 base salary, a 125% target cash bonus and an equity award with a $4,500,000 grant date fair value for the fiscal year ending June 30, 2027.
Thene will become Executive Chairman on July 1, 2026, with a $1,000,000 base salary, a 100% target cash bonus and an equity award with a $2,000,000 grant date fair value for the same fiscal year.
TransDigm Inc., a subsidiary of TransDigm Group, completed $1.5 billion of new debt on April 17, 2026: $500 million of 6.125% senior subordinated notes due 2034 and $1.0 billion of tranche N term loans due 2033. The company plans to use the proceeds, with cash on hand, to fund the purchase price of the expected Stellant Systems acquisition and about $800 million of share repurchases made in March 2026.
New notes: $500 million of 6.125% senior subordinated notes maturing July 31, 2034, issued at 100.375% of principal
New term loans: $1.0 billion at Term SOFR plus 2.50%, maturing February 13, 2033, fully drawn April 17, 2026
Proceeds to fund Stellant Systems acquisition and about $800 million of common share repurchases completed in March 2026
Mustang Bio received a Nasdaq notice on April 15, 2026, saying its common stock closed below $1.00 per share for 30 consecutive business days, so it is not in compliance with the minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company has until October 12, 2026 to regain compliance, and there is no assurance it will keep its Nasdaq listing.
Nasdaq notice received April 15, 2026; bid price closed below $1.00 for 30 consecutive business days
Compliance deadline is October 12, 2026, a 180-calendar day grace period
Compliance requires a closing bid price of at least $1.00 for a minimum of ten consecutive business days
Company may be eligible for a second 180-day period or may need a reverse stock split; no decision has been made
Badger Meter reported first-quarter 2026 sales of $202.3 million, down 9% from $222.2 million a year earlier, and diluted EPS of $0.93 versus $1.30. The company attributed the decline to project timing and weaker short-cycle orders, and it agreed to acquire UDlive, which is expected to close at the end of April 2026. Management expects full-year 2026 revenue, excluding acquisitions, to be relatively flat versus 2025.
Net sales were $202.3 million, down 9% from $222.2 million in the first quarter of 2025.
Operating earnings were $35.2 million, with a 17.4% operating margin, compared with $49.4 million and 22.2% a year earlier.
Diluted EPS was $0.93, compared with $1.30 in the prior-year quarter.
Full-year 2026 revenue, excluding acquisitions, is expected to be relatively flat versus 2025; UDlive acquisition expected to close at the end of April 2026.
Trevi Therapeutics agreed to sell 11.6 million new common shares at $13.00 each, for about $150 million before fees, with the Company estimating net proceeds of about $141.1 million. The Company said it had about $171.8 million in cash and securities as of March 31, 2026, and that this cash plus the offering proceeds will fund operations through 2029, while the sale also adds new shares outstanding for existing holders.
Offering of 11.6 million shares at $13.00 per share, with underwriters at $12.22 per share; closing expected on or about April 20, 2026.
Estimated net proceeds of about $141.1 million, or about $162.4 million if the 1,740,000-share underwriter option is exercised in full.
Cash, cash equivalents and marketable securities of about $171.8 million as of March 31, 2026, preliminary and unreviewed by the auditor.
Company expects cash to fund operations through 2029; first Phase 3 trial topline results expected in the first half of 2028.
Fifth Third reported first-quarter 2026 net income available to common shareholders of $128 million, or $0.15 per diluted share, down from $699 million ($1.04) in the prior quarter and $478 million ($0.71) a year earlier. The results include two months of Comerica, which the company acquired on February 1, 2026, and merger-related charges that reduced diluted EPS by $0.68, so revenue growth did not carry through to profit.
Net interest income rose 34% year over year to $1.939 billion, and noninterest income rose 29% to $895 million.
Noninterest expense was $2.395 billion, including $635 million of pre-tax merger-related charges; after-tax merger-related charges were $510 million.
Comerica acquisition closed February 1, 2026, in an all-stock deal valued at approximately $12.7 billion; the CET1 capital ratio fell to 9.96% from 10.81% in the prior quarter.
No share repurchases occurred in the first quarter of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.